

Prescient successfully completes \$6 million raise across Share Purchase Plan and Placement

Key Highlights:

- Prescient Therapeutics (ASX:PTX) has raised circa \$4.8 million via the Share Purchase Plan (SPP) and circa \$1.2 million in the shortfall Placement.
- The total of circa \$6 million raised provides additional funding to advance the ongoing development of PTX-100 beyond the Dose Optimisation Committee meeting, scheduled for December 2026, and into the next phase of development.

MELBOURNE Australia, 23 September 2026 – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing targeted cancer therapies, is pleased to announce that it has successfully completed a raise totaling circa \$6 million across a Share Purchase Plan (SPP) and Placement.

The Share Purchase Plan received continued support from existing Shareholders and raised a total of \$4,798,108 million (after final reconciliation). Shares issued under the SPP are expected to be allotted on or about Wednesday, 30th September 2026.

The follow-on placement was supported by sophisticated and professional investors and raised \$1,203,699.96 million for a combined raise of circa \$6 million. The issue price of the shares under the Placement was \$0.065 (6.5 cents), the same price as the shares to be issued under the SPP. Approximately 18,518,453 new shares are expected to be issued under the Placement. Shares issued under the Placement are expected to be allotted on or about Wednesday, 30th September 2026.

The funds raised will strengthen Prescient's cash position and provide additional funding for the continued development of PTX-100 beyond the first Dose Optimisation Committee review, scheduled for December 2026. The Committee will recommend the dose to be carried forward and provide guidance on continuation of the study. The program aims to progress, subject to clinical results, toward regulatory approval and broader patient access in an area of significant unmet medical need.

Prescient CEO James McDonnell said, “I want to thank our shareholders, both existing and new, for their continued support of Prescient and our mission to improve outcomes for cancer patients. This raise is an important step forward, funding the progress of PTX-100 through Phase 2a. We look forward to the milestones ahead, including the opportunity to advance PTX-100 into a Phase 2b study with registrational potential and, ultimately, toward commercialisation - whether by bringing PTX-100 to market ourselves or through a partnering outcome.”

To stay updated with the latest company news and announcements, please update your details in our [investor centre](#).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor & Media enquiries

Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of

CTCL. The Phase 2 study in r/r Cutaneous T-cell lymphoma (CTCL) is recruiting globally. With 20 evaluable patients (10 in each dosing arm) now enrolled, the first Dose Optimisation Committee review will take place in December 2026. Enrollment continues towards the planned 40 evaluable patients.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in preclinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pretreated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

Forward Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.